BUSINESS
Biocon to absorb biologics unit, eyes Rs 4,500 cr fund raise to buy Viatris’s residual stake
“When we created Biocon Biologics as a separate entity, the objective was clearly to attract investments and build global scale in biosimilars. We did that successfully, even acquiring Viatris’ biosimilars business for $3 billion. But markets kept devaluing both Biocon and Biocon Biologics because of debt overhang and holding company discount. Folding Biologics back into Biocon unlocks true value and gives us a much stronger balance sheet,” Mazumdar-Shaw said.
BUSINESS
Aurobindo Group in mega infra push, to develop Kakinada port, SEZ as industrial-logistics hub
The aim is to make Kakinada a multi-product logistics hub. ‘This is not just ships coming and going — it’s a 50-year vision,’ Kakinada Gateway Port Ltd MD Ram Reddy Ojili tells Moneycontrol
BUSINESS
Bombay High Court rejects Lilavati Trust’s Rs 17 Crore recovery claim for lack of statutory consent
The court held that the trust failed to comply with Sections 50 and 51 of the MPT Act, which require prior approval for suits involving trustees and public trust property.
BUSINESS
Indian pharma eyes US biosimilars boom as USFDA eases rules
The US biosimilars market is projected to balloon from about $22.6 billion in 2025 to more than $90 billion by 2034, according to industry estimates.
BUSINESS
Delhi High Court allows Dr Reddy’s to make weight-loss drug for exports
The company, however, cannot sell the drug in the country till March 2026, when Novo Nordisk’s secondary patent expires
BUSINESS
Wockhardt’s Zaynich NDA gets USFDA acceptance: What India’s first NCE means for the company
The next critical steps in the USFDA process involve a rigorous on-site evaluation: "visiting manufacturing facilities, inspecting documents, and so on".
BUSINESS
“Very confident of positive outcome”: Habil Khorakiwala on USFDA acceptance of Wockhardt’s NDA for its novel antibiotic
Khorakiwala said the Mumbai-based drugmaker is already laying groundwork for commercialization, with options ranging from solo marketing to partnerships in the US.
TRENDS
Cipla’s respiratory push: Sets up diagnostic centre in Delhi, Mumbai and other cities next
Cipla's wants to create awareness, help diagnostics, provide solutions and rehab support, COO Achin Gupta tells Moneycontrol, as the firm doubls down on its lung-care strategy
BUSINESS
Rainbow Hospitals targets 3,165 beds by FY29, eyes high-birth North India as key growth engine
'North India is where the future demand lies, 60% of India’s 28.5 million annual births happen in UP, Bihar, Rajasthan and Haryana,' said Dr. Ramesh Kancharla, Chairman and MD in an interview to Moneycontrol
TRENDS
Civil society groups push back as govt agencies mull data exclusivity in drug rules
Civil society groups, in a letter to Health Minister J.P. Nadda and Commerce Minister Piyush Goyal, urged the government to reject the proposal, arguing it would extend monopolies beyond the 20-year patent term and inflate drug prices.
BUSINESS
Toxic air fuels sale of respiratory drugs, segment grows 14.7% in October
Cipla, a market leader in respiratory segment, advances to the second position from third, replacing Abbott in October
BUSINESS
BlackRock to exit Bengaluru-based People Tree Hospitals
Co-founder and CEO, Dr. Jothi Neeraja, has begun facilitating the exit of US asset manager BlackRock, which invested Rs.210 crore ($24 million) in March 2025
BUSINESS
Rs 10,000 crore lost to health insurance fraud: vague symptoms, mid-ticket bills, and ID swaps top the list
Fraud hotspots are concentrated in retail health policies, reimbursement claims, and mid-ticket bills, the report said.
BUSINESS
Biological E secures WHO prequalification for pneumococcal conjugate vaccine
The WHO prequalification allows the PNEUBEVAX 14 (BE-PCV-14) vaccine to be procured by United Nations agencies and global immunization initiatives.
BUSINESS
From burn to earn: PharmEasy targets profitability by March FY27 under new CEO
Since taking charge as MD & CEO of API Holdings parent of PharmEasy in August, Rahul Guha is pivoting the group from growth-at-any-cost to profit-first execution, tightening costs, rejigging capital, and pushing higher‑margin products and services across the ecosystem.
BUSINESS
Healthium Medtech to invest Rs 150 crore in Andhra Pradesh manufacturing expansion
The new plant will boost production of surgical and post-surgical devices and create 300 direct jobs by 2027, alongside 100 indirect roles in supply chain and ancillary services.
BUSINESS
Telangana police arrest two in $250 million cyber-extortion case linked to Hetero Drugs
The accused, identified as Gadi Manikanta and Yendapalli Jessy Sudarshan, allegedly impersonated USFDA officials using fake email IDs and encrypted messaging apps, including Signal, to pressure Hetero, a release issued by Cyberabad police said.
HEALTH-AND-FITNESS
New generation drugs for cholesterol, fatty liver & kidney disease, and what they promise
These drugs promise faster results with fewer side effects, and in some cases, reversal or slows the disease progression.
BUSINESS
Mankind Pharma hit by domestic slowdown, slow BSV synergy and GST 2.0, but margin guidance intact
Mankind Pharma CEO Sheetal Arora has attributed the slowdown to GST 2.0 disruptions and uneven monsoon.
BUSINESS
AstraZeneca partners with Sun Pharma to expand access to hyperkalaemia treatment Lokelma
Under the agreement, AstraZeneca will sell SZC under the brand Lokelma, while Sun Pharma will distribute it as Gimliand.
BUSINESS
Biocon CEO sees USFDA draft rules potentially slashing biosimilar development costs by half
Global biosimilar development typically costs between $100 million and $200 million, but the U.S. Food and Drug Administration’s updated recommendations aim to eliminate expensive comparative efficacy studies, relying instead on advanced analytical and pharmacokinetic data.
BUSINESS
OneSource Specialty posts Rs 44.9 crore net profit
Chief Executive Officer Neeraj Sharma said the performance was driven by master service agreements and sales from the company’s IP-led base business.
BUSINESS
Eris Lifesciences net profit jumps 39 percent YoY to Rs 134 crore
Revenue rose 6.9 percent YoY to Rs.792 crore.
BUSINESS
Biocon reports Rs 85 crore net profit in Q2FY26
Consolidated revenue grew 11% year-on-year to Rs. 4,389 crore, led by a 25% jump in biosimilars, which contributed 61% of segmental revenue.
